Skip to content

FP7H2020HORIZON

Glaxosmithkline Research & Development Limited

Country
GBUnited Kingdom
Projects
87
As coordinator
7
EU contribution (CORDIS)
EUR 2,550,777
Active
2008 to 2026

Projects

87 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
StraDiVariousDoctoral Network on Strains, Diagnostics and VariantsHORIZON2026Associated partnerNot stated
READIResearch in Europe and Diversity InclusionHORIZON2025ParticipantEUR 0
VICT3RDeveloping and implementing VIrtual Control groups To reducE animal use in toxicology ResearchHORIZON2024ParticipantNot stated
PharmEcoAdvancing Safe and Sustainable by design Practices in Pharmaceutical ManufacturingHORIZON2024ParticipantEUR 0
Project-COMFORTPatient-Centric blOod saMpling FOr impRoved healThcare (Project-COMFORT)HORIZON2024ParticipantEUR 0
NHPigReducing Non-Human Primates in Non-Clinical Safety Assessment: The European Initiative on Minipig and Micropig ModelsHORIZON2024ParticipantEUR 0
PharmaLedgerPharmaLedgerH20202020ParticipantEUR 0
INNODIA HARVESTTranslational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIAH20202020ParticipantEUR 0
ImmUniverseBetter control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsiesH20202020ParticipantEUR 0
PREMIERPrioritisation and Risk Evaluation of Medicines in the EnviRonmentH20202020ParticipantEUR 0
MUSIQMultiphoton Microscopy and Ultrafast Spectroscopy: Imaging meets QuantumH20202019ParticipantEUR 303,173
UBIMOTIFShort linear interaction motifs as specificity determinants in the ubiquitin system – discovery, mechanisms and therapeutic opportunitiesH20202019ParticipantEUR 85,899
ConcePTIONBuilding an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generationH20202019ParticipantEUR 0
MELLODDYMachinE Learning Ledger Orchestration for Drug DiscoverYH20202019ParticipantEUR 0
COMBINECollaboration for Prevention and Treatment of MDR Bacterial InfectionsH20202019ParticipantEUR 0
NECESSITYNEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patientsH20202019ParticipantEUR 0
3TRIdentification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic ConditionsH20202019ParticipantEUR 0
AB-DiRecTAntibiotic Distribution and Recovery in TissueH20202019ParticipantEUR 0
IMMUcanIntegrated IMMUnoprofiling of large adaptive CANcer patients cohortsH20202019ParticipantEUR 0
FAIRplusFAIRplusH20202019ParticipantEUR 0

The country is the one the source records for the organisation’s registration (its PIC). A body with sites in several countries is recorded under one of them, which is not always its legal seat: the Spanish research council CSIC, for example, appears under Italy. The data holds no country per site, so we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.